The Clinical and Regulatory Milestone of Zongertinib in First-Line NSCLC
FDA grants accelerated first-line approval to zongertinib, a selective oral HER2 TKI, redefining treatment for HER2-mutant metastatic NSCLC with high response rates and precision-first strategy.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.